Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#81 / 113 Total
GDTC - CytoMed Therapeutics Ltd - Stock Price Chart
TickerGDTC [NASD]
CompanyCytoMed Therapeutics Ltd
CountrySingapore
IndustryBiotechnology
Market Cap24.35MEPS (ttm)-0.27
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B2.85EPS Q/Q9.49%
Dividend-Sales Q/Q-
Insider Own59.01%Inst Own0.00%
Insider Trans0.00%Inst Trans-
Short Float0.83%EarningsMay 29
Analyst Recom1.00Target Price5.00
Avg Volume66.31K52W Range1.88 - 5.50
Jul-17-24 07:00AM Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire) +14.29%
07:00AM CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (?d) T Cells Technology for Solid and Liquid Cancers (GlobeNewswire)
07:00AM CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta ( ) T Cells Technology for Solid and Liquid Cancers (GlobeNewswire)
Jul-16-24 07:00AM Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Mar-20-24 08:30AM CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration (ACCESSWIRE) -5.60%
Mar-18-24 06:00AM CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies (GlobeNewswire) +5.63%
Mar-04-24 05:00AM CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair (GlobeNewswire)
Jan-29-24 07:00AM Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology (GlobeNewswire)
Dec-05-23 07:30AM CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology (PR Newswire)
Nov-17-23 09:21AM CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update (PR Newswire) -8.60%
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.
RELI - Reliance Global Group Inc - Stock Price Chart
TickerRELI [NASD]
CompanyReliance Global Group Inc
CountryUSA
IndustryInsurance Brokers
Market Cap3.82MEPS (ttm)-88.11
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.28EPS next 5Y-
P/B0.71EPS Q/Q29.28%
Dividend-Sales Q/Q3.64%
Insider Own12.31%Inst Own2.67%
Insider Trans153.64%Inst Trans-
Short Float5.19%EarningsMay 20/a
Analyst Recom1.00Target Price119.00
Avg Volume658.28K52W Range3.30 - 75.82
Reliance Global Group, Inc. is a diversified company, which engages in the business of insurance market and other relates sectors. It focuses on acquisition strategy, wholesale, and retail insurance agencies. The company was founded on August 2, 2013 and is headquartered in Lakewood, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Beyman EzraChairman and CEOJun 26 '24Buy0.2830,0008,502527,100Jun 28 06:10 AM
Markovits JoelChief Financial OfficerJun 18 '24Sale0.7027,00018,976184,338Jul 16 03:39 PM
Beyman YaakovExec VP, Insurance DivisionJun 18 '24Sale0.7815,00011,72843,783Jun 21 04:05 PM
Beyman EzraChairman and CEOMay 30 '24Buy0.27186,00050,220303,886May 30 07:34 PM
GRI - GRI Bio Inc - Stock Price Chart
TickerGRI [NASD]
CompanyGRI Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap0.98MEPS (ttm)-347.34
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y26.64%
P/S-EPS next 5Y-
P/B0.14EPS Q/Q98.77%
Dividend-Sales Q/Q-
Insider Own1.50%Inst Own2.98%
Insider Trans0.00%Inst Trans-
Short Float14.07%EarningsApr 01/b
Analyst Recom1.00Target Price32760.00
Avg Volume138.22K52W Range1.46 - 370.37
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
SHIM - Shimmick Corp. - Stock Price Chart
TickerSHIM [NASD]
CompanyShimmick Corp.
CountryUSA
IndustryEngineering & Construction
Market Cap91.74MEPS (ttm)-
P/E-EPS this Y-401.04%
Forward P/E-EPS next Y93.77%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.96EPS Q/Q-285.06%
Dividend-Sales Q/Q-34.89%
Insider Own0.00%Inst Own7.23%
Insider Trans-Inst Trans-
Short Float0.21%EarningsMay 13/a
Analyst Recom3.00Target Price3.75
Avg Volume846.27K52W Range1.47 - 7.99
Shimmick Corp. engages in the provision of water and other critical infrastructure solutions. The company was founded in 1990 and is headquartered in Irvine, CA.
TCBI - Texas Capital Bancshares, Inc. - Stock Price Chart
TickerTCBI [NASD, RUT]
CompanyTexas Capital Bancshares, Inc.
CountryUSA
IndustryBanks - Regional
Market Cap3.11BEPS (ttm)3.30
P/E20.23EPS this Y-1.25%
Forward P/E15.97EPS next Y19.49%
PEG2.53EPS past 5Y-9.39%
P/S1.71EPS next 5Y8.00%
P/B1.09EPS Q/Q-34.89%
Dividend-Sales Q/Q8.14%
Insider Own2.43%Inst Own101.08%
Insider Trans8.87%Inst Trans-3.89%
Short Float3.45%EarningsJul 18/b
Analyst Recom2.93Target Price63.07
Avg Volume379.65K52W Range52.89 - 72.07
Texas Capital Bancshares, Inc. is a holding company, which engages in the provision of financial services and customized solutions to businesses, entrepreneurs, and individual customers. The company was founded by George F. Jones, Jr. and Joseph M. Grant in November 1996 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Storms Timothy JChief Risk OfficerJun 13 '24Option Exercise0.00205016,571Jun 14 05:04 PM
Scurlock John MatthewChief Financial OfficerJun 03 '24Option Exercise0.00240011,090Jun 04 04:34 PM
STALLINGS ROBERT WDirectorMay 23 '24Buy39.5810,369410,368174,706May 24 04:26 PM
STALLINGS ROBERT WDirectorMay 22 '24Buy19.363,00058,080169,706May 24 04:26 PM
STALLINGS ROBERT WDirectorMay 21 '24Buy19.483,00058,440166,706May 22 04:34 PM
GUTS - Fractyl Health Inc. - Stock Price Chart
TickerGUTS [NASD, RUT]
CompanyFractyl Health Inc.
CountryUSA
IndustryBiotechnology
Market Cap213.39MEPS (ttm)-
P/E-EPS this Y95.61%
Forward P/E-EPS next Y-22.86%
PEG-EPS past 5Y-126.07%
P/S-EPS next 5Y-
P/B2.53EPS Q/Q66.90%
Dividend-Sales Q/Q-
Insider Own58.50%Inst Own29.48%
Insider Trans5.52%Inst Trans-
Short Float10.27%EarningsMay 13/a
Analyst Recom1.00Target Price20.00
Avg Volume177.60K52W Range3.98 - 14.50
Jun-25-24 09:02AM FDA expands Fractyl endoscopy trial to include untreated diabetes patients (Medical Device Network) -9.22%
07:00AM Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day (GlobeNewswire)
Jun-24-24 06:00AM Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates (GlobeNewswire) +5.76%
Jun-23-24 01:30PM Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-29-24 07:00AM Fractyl Health to Present New Preclinical Obesity Data from Rejuva Platform at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-20-24 06:00AM Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024 (GlobeNewswire)
May-13-24 08:56PM GUTS Stock Earnings: Fractyl Health Beats EPS for Q1 2024 (InvestorPlace) +8.52%
04:00PM Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
11:41AM Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes (MT Newswires)
06:00AM Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) (GlobeNewswire)
Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elia MarcDirectorFeb 06 '24Buy15.00466,6666,999,9901,856,117Feb 08 04:32 PM
CVF, LLC10% OwnerFeb 06 '24Buy15.00333,3334,999,9954,673,870Feb 06 08:39 PM
Mithril LP10% OwnerFeb 06 '24Buy15.00333,3334,999,9951,251,900Feb 08 04:35 PM
Royan AjayDirectorFeb 06 '24Buy15.00333,3334,999,9951,251,900Feb 08 04:37 PM
TFIN - Triumph Financial Inc - Stock Price Chart
TickerTFIN [NASD, RUT]
CompanyTriumph Financial Inc
CountryUSA
IndustryBanks - Regional
Market Cap2.06BEPS (ttm)1.11
P/E79.69EPS this Y-35.42%
Forward P/E38.30EPS next Y122.16%
PEG6.64EPS past 5Y-4.55%
P/S4.26EPS next 5Y12.00%
P/B2.49EPS Q/Q-71.85%
Dividend-Sales Q/Q5.04%
Insider Own7.05%Inst Own95.18%
Insider Trans-3.07%Inst Trans-3.23%
Short Float10.43%EarningsJul 17/a
Analyst Recom3.33Target Price68.40
Avg Volume188.50K52W Range56.91 - 95.46
Triumph Financial, Inc. is a holding company, which engages in offering traditional banking and financial solutions. It operates through the following segments: Banking, Factoring, Payments, and Corporate. The Banking segment relates to traditional banking services. The Factoring segment includes the operations of Triumph Business Capital, which offers factoring services. The Payments segment offers a payment network for the over-the-road trucking industry. The Corporate segment refers to the financing, investment activities, management and administrative expenses. The company was founded by Aaron P. Graft on November 10, 2003 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nelson Adam DEVP and General CounselJul 11 '24Option Exercise26.254,598120,69836,883Jul 12 04:49 PM
Nelson Adam DEVP and General CounselJul 11 '24Sale87.274,598401,26732,285Jul 12 04:49 PM
Ritterbusch ToddPresident - TBK Bank, SSBMay 13 '24Sale74.073,000222,2107,434May 14 04:28 PM
Ritterbusch ToddPresident - TBK Bank, SSBMay 10 '24Sale73.847,854579,93910,434May 14 04:28 PM
Forman-Barenblit MelissaEVP, Pres-TriumphPay-TBK BankMay 06 '24Sale73.742,780204,9979,808May 08 04:00 PM
STIM - Neuronetics Inc - Stock Price Chart
TickerSTIM [NASD]
CompanyNeuronetics Inc
CountryUSA
IndustryDiagnostics & Research
Market Cap56.70MEPS (ttm)-0.95
P/E-EPS this Y11.75%
Forward P/E-EPS next Y30.10%
PEG-EPS past 5Y17.12%
P/S0.77EPS next 5Y-
P/B2.05EPS Q/Q28.83%
Dividend-Sales Q/Q12.08%
Insider Own6.93%Inst Own63.52%
Insider Trans-5.93%Inst Trans-1.98%
Short Float0.43%EarningsMay 07/b
Analyst Recom1.00Target Price7.00
Avg Volume141.20K52W Range1.03 - 5.07
Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CASCELLA ROBERTDirectorJun 06 '24Buy2.0550,000102,550244,098Jun 06 05:15 PM
MACAN WILLIAM ANDREWEVP, GC, CCO and CSFeb 29 '24Sale2.946,02617,716389,333Mar 01 05:02 PM
MACAN WILLIAM ANDREWEVP, GC, CCO and CSFeb 28 '24Sale3.1622,37770,711395,359Mar 01 05:02 PM
Furlong StephenEVP, CFO and TreasurerFeb 28 '24Sale3.163,98512,593483,776Feb 29 05:02 PM
Furlong StephenEVP, CFO and TreasurerFeb 27 '24Sale3.3321,27270,836487,761Feb 29 05:02 PM
ABCL - AbCellera Biologics Inc - Stock Price Chart
TickerABCL [NASD]
CompanyAbCellera Biologics Inc
CountryCanada
IndustryBiotechnology
Market Cap936.55MEPS (ttm)-0.51
P/E-EPS this Y6.32%
Forward P/E-EPS next Y-6.14%
PEG-EPS past 5Y-
P/S26.17EPS next 5Y10.00%
P/B0.83EPS Q/Q0.50%
Dividend-Sales Q/Q-18.36%
Insider Own29.84%Inst Own38.64%
Insider Trans0.00%Inst Trans11.09%
Short Float9.10%EarningsAug 06/a
Analyst Recom1.00Target Price14.38
Avg Volume1.69M52W Range2.65 - 8.05
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Veronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
HXL - Hexcel Corp. - Stock Price Chart
TickerHXL [NYSE]
CompanyHexcel Corp.
CountryUSA
IndustryAerospace & Defense
Market Cap5.34BEPS (ttm)1.16
P/E55.20EPS this Y21.31%
Forward P/E22.24EPS next Y31.51%
PEG2.36EPS past 5Y-16.84%
P/S2.97EPS next 5Y23.36%
P/B3.27EPS Q/Q-13.82%
Dividend0.94%Sales Q/Q1.72%
Insider Own0.73%Inst Own96.72%
Insider Trans7.83%Inst Trans1.73%
Short Float1.27%EarningsJul 18/b
Analyst Recom2.45Target Price75.53
Avg Volume1.01M52W Range58.81 - 77.46
Hexcel Corp. engages in the development, manufacture, and marketing of lightweight structural materials. It operates through the Composite Materials and Engineered Products segments. The Composite Materials segment includes carbon fiber, specialty reinforcements, resins, prepregs and other fiber-reinforced matrix materials, and honeycomb core product lines and pultruded profiles. The Engineered Products segment refers to the lightweight high strength composite structures, engineered core and honeycomb products with added functionality, and additive manufacturing. The company was founded by Roger C. Steele and Roscoe T. Hughes in 1946 and is headquartered in Stamford, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Suever Catherine ADirectorJul 14 '24Option Exercise0.00288017,718Jul 15 04:00 PM
Suever Catherine ADirectorMay 04 '24Option Exercise0.001,682017,430May 06 04:00 PM
Suever Catherine ADirectorMay 03 '24Buy68.3340027,33215,748May 06 04:00 PM
Gentile TomCEO and PresidentMay 01 '24Buy66.2515,000993,76315,000May 02 04:26 PM
HACHEY GUY CDirectorApr 29 '24Buy64.533,000193,5903,000Apr 30 04:04 PM
1456789101112